BTIG Reiterates Buy Rating on Spyre Therapeutics, Sets $121 Target
BTIG reiterated its Buy rating and $121 price target. The target implies 51.4% upside from the Oct. 16 close of $79.90.
BTIG reiterated its Buy rating and $121 price target. The target implies 51.4% upside from the Oct. 16 close of $79.90.